Lumen Medical

Lumen Bioscience is a clinical-stage biotechnology company that has pioneered a novel platform for developing and manufacturing orally delivered biologic drugs using the edible microalgae Spirulina. By engineering Spirulina to produce therapeutic proteins such as antibodies, the company can deliver high-concentration biologics directly to the gastrointestinal tract, bypassing the need for systemic injection and complex purification. Their lead program, LMN-201, is currently in Phase 2 clinical trials for the prevention of Clostridioides difficile infection recurrence. The company's technology significantly reduces the cost and time required for biologic drug development, enabling scalable solutions for prevalent infectious and inflammatory diseases.